Granules India Limited is a pharmaceutical manufacturing company based in India. The company is engaged in the production and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). With a strong focus on quality, innovation, and customer satisfaction, Granules India has established itself as a reliable player in the pharmaceutical industry. The company’s primary segment is the manufacturing of APIs, which are the essential components of pharmaceutical drugs.
- Granules India Limited reported Total Income for Q4 FY23 of ₹1,198.87 Crore up from ₹1,033.93 Crore year on year, a growth of 16%.
- Total Expenses for Q4 FY23 of ₹1,034.89 Crore up from ₹883.81 Crore year on year, a growth of 17.1%.
- Consolidated Net Profit of ₹119.60 Crore, up 7.7% from ₹111 Crore in the same quarter of the previous year.
- The Earnings per Share is ₹4.93, from ₹4.46 in the same quarter of the previous year.